• Wondering whether AnaptysBio at around US$66.76 is still worth your attention, or if most of the value story is already reflected in the price?
• The stock has posted returns of 13.4% over the last 7 days, 17.7% over 30 days, 48.5% year to date, and 372.7% over the past year. This will naturally raise questions about how those moves line up with the underlying value.
• Recent coverage has focused on AnaptysBio's position in the biotech space and how sentiment around its pipeline and partnerships may be shaping expectations for the company. This context matters, because shifts in how the market views risk and potential outcomes can have a direct impact on what investors are willing to pay for each share.
• On Simply Wall St's valuation checks, AnaptysBio currently holds a value score of 3 out of 6. Next up is a closer look at how different valuation methods stack up for this stock and why a more holistic framework later in the article can be even more useful when you are weighing what to do next.

Approach 1: AnaptysBio Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model projects a company’s future cash flows and then discounts them back to today’s value using a required rate of return. It is essentially asking what those future cash flows are worth in current dollars.

For AnaptysBio, Simply Wall St uses a 2 Stage Free Cash Flow to Equity model based on cash flow projections in $. The latest twelve month free cash flow is about $18.8 million. Analyst estimates and subsequent extrapolations point to free cash flow of $32.7 million in 2026 and $286.5 million by 2030, with further forecast figures beyond that date generated by the model rather than by analysts.

Putting these projections together, the DCF output suggests an estimated intrinsic value of about $334.74 per share. Compared with the recent share price of around $66.76, this implies an intrinsic discount of roughly 80.1%, which indicates that the shares are trading below the model’s estimate of value based on projected cash flows.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests AnaptysBio is undervalued by 80.1%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: AnaptysBio Price vs Sales

For a biotech like AnaptysBio where earnings can be volatile, the P/S ratio is often more useful than P/E because it anchors valuation to current revenue rather than fluctuating profits or losses.

Growth expectations and risk still matter, because investors usually accept a higher or lower P/S based on how quickly they expect sales to expand and how confident they are that those sales will be sustained. That context helps frame what looks like a “normal” multiple for a company.

AnaptysBio currently trades on a P/S of 8.18x. This is close to the peer average of 8.15x and below the broader Biotechs industry average of 11.01x. Simply Wall St also calculates a “Fair Ratio” of 4.46x, which is the P/S level suggested by factors such as the company’s growth profile, margins, industry, market cap and risk characteristics.

This Fair Ratio is more tailored than a simple comparison with peers or the industry because it adjusts for company specific traits rather than assuming that one size fits all. Comparing 8.18x with a Fair Ratio of 4.46x indicates that AnaptysBio is trading above that model based estimate.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your AnaptysBio Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are worth introducing as a simple idea. You write the story you believe about a company, then connect that story to your assumptions for future revenue, earnings and margins. These then link through to a fair value estimate that can be compared with the current share price to help guide your decision making. This can all be done within an easy tool on Simply Wall St's Community page that is updated automatically when new information such as news or earnings arrives. For AnaptysBio this can mean one investor sets a very high fair value based on an optimistic view of the pipeline, while another sets a much lower fair value based on more cautious assumptions.

Do you think there's more to the story for AnaptysBio? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.